Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Edesa Biotech ( (EDSA) ) has issued an update.
Edesa Biotech is advancing its vitiligo program, confirming that site activations and patient recruitment for a Phase 2 trial of its monoclonal antibody candidate EB06 in moderate-to-severe nonsegmental vitiligo are planned to begin in mid-2026, starting in Canada. The company has appointed JSS Medical Research as its clinical research organization, and is leveraging ongoing engagement with vitiligo key opinion leaders to refine trial design, underscoring its bid to address a high-prevalence disease with few effective treatments and no approved systemic therapies targeting the underlying autoimmune process.
The Phase 2 study will test the safety and efficacy of intravenous EB06 versus placebo, building on earlier clinical and preclinical data showing that neutralizing the chemokine CXCL10 can prevent and reverse depigmentation by disrupting T-cell–mediated melanocyte destruction. If successful, the program could position Edesa as a notable player in medical dermatology by offering a targeted biologic option for patients with extensive vitiligo, with a subcutaneous formulation also planned for future clinical evaluation.
The most recent analyst rating on (EDSA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.
Spark’s Take on EDSA Stock
According to Spark, TipRanks’ AI Analyst, EDSA is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn). Technicals are strong with price well above moving averages and positive MACD, but elevated RSI suggests the move may be overextended. A positive catalyst is the reported Phase 3 clinical data, which supports the pipeline outlook, while valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on EDSA stock, click here.
More about Edesa Biotech
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for inflammatory and immune-related diseases. The Toronto-based firm concentrates on medical dermatology and respiratory indications, with key assets including EB06, an anti-CXCL10 monoclonal antibody for vitiligo, and additional dermatology candidates in late-stage development.
Average Trading Volume: 4,403,078
Technical Sentiment Signal: Buy
Current Market Cap: $54.85M
Find detailed analytics on EDSA stock on TipRanks’ Stock Analysis page.